OUTCOMES OF TRIPLE NEGATIVE BREAST CANCER IN EARLY BREAST CANCER

WITH NEO ADJUVANT CHEMOTHERAPY

Submission: 07 December 2025 | Acceptance: 02 March 2026 | Publication: 29 April 2026

1Dr Bushra Malik, 2Dr Muhammad Tariq, 3Dr Asiya Hassan, 4Dr Maryam bibi, 5Dr Kiran

Shaheen, 6Dr Irum Sabir

1Pgr medical oncology MTI KTH PESHAWAR

2Assistant professor Department of medical oncology MTI KTH PESHAWAR

3Consultant IKD PESHAWAR

4Pgr medical oncology MTI KTH PESHAWAR

5Pgr medical oncology MTI KTH PESHAWAR

6Associate Professor Department of surgery / breast unit, MTI KTH PESHAWAR

Corresponding: Dr Muhammad Tariq, Assistant professor Department of medical oncology MTI KTH

PESHAWAR

Abstract:

Objectives: To determine the outcomes of triple negative breast cancer in early breast cancer with neo

adjuvant chemotherapy.

Materials and Methods: After approval from the review board, patients were enrolled following written

informed consent for voluntary participation. Data were collected from all participants, including detailed

physical examination findings and medical history. Demographic variables were noted. Patients receivedGLOBAL HEALTH & MEDICINE

ISSN / eISSN: 2434-9186 / 2434-9194 Volume 08, Issue 06.

Home

protocol-based treatment with either an immunotherapy-based regimen or standard neoadjuvant

anthracycline-based chemotherapy every three weeks for three cycles, along with standard supportive

medications. Following treatment completion, surgery was performed and specimens were sent for

histopathological evaluation. Data were recorded in a questionnaire and analyzed with SPSS 26.

Results: The majority of patients were between 31 and 40 years old, with a mean age of 42.69 ± 9.71

years and a mean BMI of 22.48 ± 4.12 kg/m². Illiteracy, housewife position, urban living, right-sided

sickness, and middling socioeconomic level were more prevalent. While there was no discernible

correlation between treatment response and age, breast laterality, or BMI, nearly half obtained complete

remission.

Conclusion: It was concluded that neoadjuvant chemotherapy plays a crucial role in the treatment of

early triple-negative breast cancer, and that the best indicator of enhanced survival is pathological full

response. To improve therapy response and optimize treatment techniques, more research is advised.

Key words: Triple negative breast cancer, neo adjuvant chemotherapy, complete response